Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCERT study of oral valganciclovir for congenital CMV-associated hearing loss
NL-OMON39229Phase 3Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of valganciclovir in congenital cytomegalovirus infection (cCMV) (2 arms), sponsored by Leiden University Medical Center. Started Sep 2012; status: active, not recruiting.
02
Drugs
valganciclovir
03
Conditions
congenital cytomegalovirus infection (cCMV)
Beyond the preview
Go deeper on NL-OMON39229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39229.